Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × HCC × 1 year × Clear all

Phase

Phase 2/3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 486 Carcinoma, Non-Small-Cell Lung 462 Prostatic Neoplasms 307 Multiple Myeloma 244 Neoplasms 235 Colorectal Neoplasms 223 Leukemia, Myeloid, Acute 200 Lung Neoplasms 196 Squamous Cell Carcinoma of Head and Neck 190 Neoplasm Metastasis 179 Carcinoma, Hepatocellular 174 Pancreatic Neoplasms 164 Melanoma 157 Triple Negative Breast Neoplasms 151 Ovarian Neoplasms 137 Recurrence 136 Glioblastoma 125 Lymphoma 124 Brain Neoplasms 124 Leukemia, Lymphocytic, Chronic, B-Cell 114 Stomach Neoplasms 109 Sarcoma 109 Precursor Cell Lymphoblastic Leukemia-Lymphoma 109 Lymphoma, Large B-Cell, Diffuse 108 Carcinoma, Renal Cell 107 Head and Neck Neoplasms 104 Myelodysplastic Syndromes 96 Rectal Neoplasms 90 Uterine Cervical Neoplasms 88 Small Cell Lung Carcinoma 88

Interventions

atezolizumab 1 Radiotherapy 1 Radiosurgery 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06823375 2026-03-04

SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis

Chinese University of Hong Kong

Phase 2 Recruiting

HCC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡